Anondita Medicare Limited has announced its participation in Pharma Eurasia 2026, Uzbekistan, a leading pharmaceutical industry exhibition. The event is scheduled to be held from 20th May 2026 to 22nd May 2026 at Tashkent Pharma Park, Tashkent, Uzbekistan. The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Event Details

The company will participate in the exhibition in physical mode, with the primary objective of expanding its presence across Central Asian countries and exploring business opportunities, including engagement with potential buyers. The key details of the event are outlined below:

Strategic Objectives

Anondita Medicare's participation in the exhibition is aligned with its broader international expansion strategy. The company intends to leverage the platform to achieve the following objectives:

• Strengthening the company's presence across Central Asian markets
• Exploring engagement opportunities with potential buyers and channel partners
• Showcasing the company's manufacturing capabilities and product portfolio in international markets
• Expanding global business visibility through participation in a leading pharmaceutical industry exhibition

Management Commentary

Commenting on the development, Mr. Anupam Ghosh, Managing Director, Anondita Medicare Limited, said: "Our participation in Pharma Eurasia 2026 reflects our continued focus on expanding our international presence and engaging with potential business partners across emerging markets. The exhibition provides an opportunity to showcase our manufacturing capabilities and explore growth opportunities in Central Asia."

About Anondita Medicare Limited

Anondita Medicare Limited is an Indian manufacturer of condoms, operating under its flagship brand "COBRA." The company runs its own manufacturing facility and follows a quality-driven, compliant production model. The company is led by Mr. Anupam Ghosh, who brings over 25 years of experience in the healthcare and contraceptive products industry. With a strong domestic presence, particularly in North India, Anondita Medicare is actively expanding its geographical footprint across India and international markets. Ongoing initiatives such as automation-led capacity enhancement and patented female condom products position the company for scalable growth and long-term value creation.

Anondita Medicare Limited has filed a newspaper publication notice with the National Stock Exchange of India Limited pursuant to Regulation 30 read with Schedule III, Regulation 47, and applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that advertisements relating to the dispatch of the EGM notice and e-voting information for its 01/2026-27 Extra-Ordinary General Meeting were published on May 7, 2026, in the Financial Express (English) and Jansatta (Hindi) newspapers. The EGM is scheduled to be held on Thursday, May 28, 2026, at 01:00 P.M. (IST) through Video Conferencing (VC) / Other Audio-Visual Means (OAVM).

Newspaper Publication Details

The regulatory filing was submitted by Bhawna Bisht, Company Secretary and Compliance Officer, on behalf of Anondita Medicare Limited. The publication confirms compliance with applicable listing regulations ahead of the scheduled EGM. The EGM notice and related information are also available on the company's website.

Preferential Issue of Warrants

The Board proposes to issue up to 2,85,000 convertible warrants to persons belonging to the promoter category on a preferential basis. The warrants will be issued at a price of ₹1,022 each, including a premium of ₹1,012, aggregating to a total issue size of ₹29,12,70,000. The sole proposed allottee is Mr. Anupam Ghosh, a promoter of the company.

The payment structure requires 25% of the warrant issue price, amounting to ₹7,28,17,500, to be paid at the time of subscription. The remaining 75%, totaling ₹21,84,52,500, is payable upon the exercise of the warrants. The warrants are convertible into fully paid-up equity shares with a face value of ₹10 each within a period of 18 months from the date of allotment. The relevant date for determining the floor price is April 27, 2026.

The proceeds from the issue are intended to be utilized for capital expenditure, infrastructure development, and marketing activities. The company states that the issue will not result in any change in control or management.

Related Party Transactions

Shareholders will also consider resolutions for material related party transactions for the financial year 2026-27. The company seeks approval to enter into transactions with Anondita Healthcare & Rubber Products (India) Limited, a subsidiary, for an aggregate value not exceeding ₹60,00,00,000. These transactions include the sale of products and the granting of unsecured loans.

Additionally, approval is sought for transactions with Mr. Anupam Ghosh, the Managing Director, involving guarantees and property rent, with an aggregate value not exceeding ₹25,50,00,000. The company also proposes to ratify material related party transactions undertaken with Anondita Healthcare and Rubber Products India Ltd. during the previous financial year, amounting to ₹42,00,00,000.

Amendments and Remuneration

The EGM agenda includes a special resolution to amend the main object clause of the Memorandum of Association. The proposed substitution aims to expand the company's business activities to include the manufacturing of sexual wellness products, diagnostic kits, and latex-based products.

Furthermore, the Board has proposed an increase in the managerial remuneration for its Whole-time Director, Mr. Reshant Ghosh, and Managing Director, Mr. Anupam Ghosh. The remuneration for Mr. Reshant Ghosh is proposed to be revised to ₹5,00,000 per month, while Mr. Anupam Ghosh's remuneration is proposed to be increased to ₹10,00,000 per month, effective from April 1, 2026.

The remote e-voting period will commence on May 25, 2026, and conclude on May 27, 2026.